NCT03775850View on ClinicalTrials.gov

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

October 31, 2021

Conditions
Colorectal Cancer MetastaticTriple Negative Breast CancerNon Small Cell Lung CancerBladder CancerGastroEsophageal CancerRenal Cell CarcinomaMSI-H
Interventions
BIOLOGICAL

EDP1503

4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)

BIOLOGICAL

Pembrolizumab

200 mg given by intravenous (IV) infusion once every 3 weeks

Trial Locations (8)

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, Nashville

37404

Tennessee Oncology, PLLC, Chattanooga

72758

Highlands Oncology Group, Rogers

73104

Stephenson Cancer Center, Oklahoma City

H2X 0A9

Centre de Recherche du CHUM, Montreal

H3T1E2

Jewish General Hospital, Montreal

G1R 2J6

CHU de Québec - Université Laval, Québec

Sponsors
All Listed Sponsors
collaborator

SCRI Development Innovations, LLC

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Evelo Biosciences, Inc.

INDUSTRY

NCT03775850 - A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Biotech Hunter | Biotech Hunter